Nanosonics Limited (ASX:NAN) is an infection-prevention company best known for trophon, a device that disinfects ultrasound probes between patients, with a large installed base across hospitals worldwide. It is now commercialising a second platform, CORIS, aimed at the cleaning of flexible endoscopes — a large, adjacent market that could materially expand its opportunity.

The launch of CORIS and the trajectory of the trophon Business have framed the question of whether the next catalyst could spark a major re-rating.

Latest Development

In the first half of FY26, Nanosonics reported total Revenue of A$102.2 million, up 9%, with its installed base growing 6% to 38,080 devices, protecting around 29 million patients a year, and a gross Margin of 76.3%. For the full year it guided to revenue of A$215–223 million, representing 8–12% growth, with gross margins of 75–77%.

On CORIS, the company achieved regulatory certifications in Australia, the European Union and the United Kingdom, completed its first 510(k) submission to the United States Food and Drug Administration, and began a controlled market release, including its first system at a United Kingdom hospital. The shares fell after the FY26 result amid margin pressure from tariffs and currency.

What Could Drive the Shares Next?

Catalysts include the commercial ramp of CORIS, United States FDA clearance and subsequent launch, continued growth in the trophon installed base, and any easing of the Tariff and currency pressures on margins. A successful CORIS rollout would be the most powerful potential re-rating driver.

Evidence that CORIS is gaining hospital adoption, alongside steady trophon growth, would be the clearest positive signal.

Risks Investors Should Watch

Margin pressure from tariffs and currency is a live concern, as the FY26 reaction showed. CORIS is early in its launch, and United States FDA timing and hospital-adoption pace are uncertain.

Nanosonics is exposed to the hospital capital-equipment cycle, and competition exists in infection prevention, so execution on the new platform is critical.

Investor Takeaway

Nanosonics grew first-half FY26 revenue 9% on a larger trophon installed base and began the controlled release of CORIS, while flagging margin pressure. Whether the next catalyst sparks a re-rating depends heavily on CORIS gaining regulatory clearance and hospital adoption. CORIS progress, United States FDA timing and margins are the things to watch.